|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Dr. Lex Van der Ploeg Has Been Elected to the Neurotez, Inc. Board of Directors
6/15/2012 10:12:31 AM
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Neurotez is announcing the appointment of Dr. Lex Van der Ploeg to the Board of Directors. Dr. Van der Ploeg will continue as Chief Scientific Advisor for Neurotez’s development plans, and will now also participate as a member of the Board of Directors. Dr. Van der Ploeg has in depth knowledge in the Neurosciences, Obesity and Oncology, applied through translational research/drug discovery, and drug development efforts at diverse pharmaceutical companies. “Lex’s background and experience are an exceptional fit for Neurotez as we move forward with our clinical efforts. Our primary program to develop Leptin for the treatment of Alzheimer’s disease, and our overarching mission as a biotech, will significantly benefit with Lex on board” said Nikolaos Tezapsidis, President & CEO of Neurotez, Inc. “I am excited about Neurotez’s programs, and the unique mechanisms which Leptin modulates for the treatment of Alzheimer’s disease” stated Lex Van der Ploeg.
|
|
|
|
|
|
|
|
|
|
|